Plasma proteome profiling identifies XPNPEP3 as a novel biomarker associated with metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus

Key Points

• This research aims to evaluate the association of plasma XPNPEP3 levels with metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with type 2 diabetes mellitus (T2DM).
• Analyzed plasma proteome profiles in T2DM patients.
• Measured XPNPEP3 levels to assess its association with MASLD.
• Evaluated the diagnostic potential of XPNPEP3 as a biomarker.
• Lower plasma XPNPEP3 levels were independently linked to MASLD in T2DM patients.
• XPNPEP3 demonstrated strong potential as a diagnostic biomarker for MASLD.